180 related articles for article (PubMed ID: 22251182)
21. Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer.
Degeling K; IJzerman MJ; Groothuis-Oudshoorn CGM; Franken MD; Koopman M; Clements MS; Koffijberg H
Value Health; 2022 Jan; 25(1):104-115. PubMed ID: 35031089
[TBL] [Abstract][Full Text] [Related]
22. Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation.
Briggs AH; Mooney CZ; Wonderling DE
Stat Med; 1999 Dec; 18(23):3245-62. PubMed ID: 10602149
[TBL] [Abstract][Full Text] [Related]
23. Using inverse-weighting in cost-effectiveness analysis with censored data.
Willan AR; Lin DY; Cook RJ; Chen EB
Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
[TBL] [Abstract][Full Text] [Related]
24. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.
Briggs AH; Wonderling DE; Mooney CZ
Health Econ; 1997; 6(4):327-40. PubMed ID: 9285227
[TBL] [Abstract][Full Text] [Related]
25. Use of an angular transformation for ratio estimation in cost-effectiveness analysis.
Cook JR; Heyse JF
Stat Med; 2000 Nov; 19(21):2989-3003. PubMed ID: 11042628
[TBL] [Abstract][Full Text] [Related]
26. Resampling and multiplicity in cost-effectiveness inference.
Obenchain RL
J Biopharm Stat; 1999 Nov; 9(4):563-82. PubMed ID: 10576404
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
28. A two-part model for censored medical cost data.
Tian L; Huang J
Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
[TBL] [Abstract][Full Text] [Related]
29. Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results.
Tambour M; Zethraeus N
Health Econ; 1998 Mar; 7(2):143-7. PubMed ID: 9565170
[TBL] [Abstract][Full Text] [Related]
30. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?
Pullenayegum EM; Tarride JE; Xie F; Goeree R; Gerstein HC; O'Reilly D
Value Health; 2010; 13(4):487-94. PubMed ID: 20230549
[TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
Gerhard T; Zineh I; Winterstein AG; Hartzema AG
Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026
[TBL] [Abstract][Full Text] [Related]
32. Statistical inference for cost-effectiveness ratios.
Laska EM; Meisner M; Siegel C
Health Econ; 1997; 6(3):229-42. PubMed ID: 9226141
[TBL] [Abstract][Full Text] [Related]
33. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
Willan AR; O'Brien BJ
Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
[TBL] [Abstract][Full Text] [Related]
34. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.
Yang F; Devlin N; Luo N
Eur J Health Econ; 2019 Feb; 20(1):99-105. PubMed ID: 29948432
[TBL] [Abstract][Full Text] [Related]
35. Correlation coefficient inference on censored bioassay data.
Li L; Wang WW; Chan IS
J Biopharm Stat; 2005; 15(3):501-12. PubMed ID: 15920894
[TBL] [Abstract][Full Text] [Related]
36. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data.
Willan AR; Briggs AH; Hoch JS
Health Econ; 2004 May; 13(5):461-75. PubMed ID: 15127426
[TBL] [Abstract][Full Text] [Related]
37. Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review.
Wong CK; Lang BH; Guo VY; Lam CL
Appl Health Econ Health Policy; 2016 Dec; 14(6):647-657. PubMed ID: 27502943
[TBL] [Abstract][Full Text] [Related]
38. A note on confidence intervals in cost-effectiveness analysis.
Tambour M; Zethraeus N; Johannesson M
Int J Technol Assess Health Care; 1998; 14(3):467-71. PubMed ID: 9780533
[TBL] [Abstract][Full Text] [Related]
39. Incremental cost-effectiveness of adult spinal deformity surgery: observed quality-adjusted life years with surgery compared with predicted quality-adjusted life years without surgery.
McCarthy I; O'Brien M; Ames C; Robinson C; Errico T; Polly DW; Hostin R;
Neurosurg Focus; 2014 May; 36(5):E3. PubMed ID: 24785485
[TBL] [Abstract][Full Text] [Related]
40. [The handling of uncertainty in economic evaluations of health care strategies].
Siani C; Moatti JP
Rev Epidemiol Sante Publique; 2003 Apr; 51(2):255-76. PubMed ID: 12876511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
